Patents by Inventor Stefan Peukert

Stefan Peukert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and Compositions for Treating Luekemia
    Publication number: 20150209365
    Abstract: A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.
    Type: Application
    Filed: April 8, 2015
    Publication date: July 30, 2015
    Applicant: Novartis AG
    Inventors: Mhairi Copland, Marion Dorsch, David Irvine, Paul W. Manley, Stefan Peukert
  • Compounds and compositions as selective estrogen receptor degraders
    Patent number: 8877801
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20140235660
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Isoquinoline derivatives
    Patent number: 8722671
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: May 13, 2014
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Cycloalkylamine substituted isoquinoline derivatives
    Patent number: 8710228
    Abstract: The invention relates to 6-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: June 18, 2009
    Date of Patent: April 29, 2014
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Matthias Löhn, Peter Monecke, Alexander Schiffer, Aimo Kannt, Markus Kohlmann
  • PYRIDAZINYL DERIVATIVES AS SMO INHIBITORS
    Publication number: 20130261299
    Abstract: The present invention relates to compounds of formula I: in which L, W, X, Y, Z, m, p, R1, R2, R3, R4 and R7 are defined in the Summary of the Invention; capable of inhibiting the Hedgehog and Smo signaling pathway. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the diagnosis and treatment of pathologies relating to the Hedgehog and Smo signaling pathway, for example, tumor formation, cancer, neoplasia and non-malignant hyperproliferative disorders.
    Type: Application
    Filed: May 30, 2013
    Publication date: October 3, 2013
    Applicant: Novartis AG
    Inventors: Feng He, Stefan Peukert, Karen Marie Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu
  • Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway
    Patent number: 8536168
    Abstract: The present disclosure relates to compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders; specifically relating to compounds of formula I:
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: September 17, 2013
    Assignee: Novartis AG
    Inventors: Miao Dai, Feng He, Rishi Kumar Jain, Rajesh Karki, Joseph Kelleher, III, John Lei, Luis Llamas, Michael A. Mcewan, Karen Miller-Moslin, Lawrence Bias Perez, Stefan Peukert, Naeem Yusuff
  • Isoquinoline derivatives
    Patent number: 8501736
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: August 6, 2013
    Assignee: Sanofi
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Pyridazinyl derivatives as smo inhibitors
    Patent number: 8481542
    Abstract: The present invention relates to compounds of formula I: in which R11 and R12 are defined in the Summary of the Invention; capable of inhibiting the Hedgehog and Smo signaling pathway. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the diagnosis and treatment of pathologies relating to the Hedgehog and Smo signaling pathway, for example, tumor formation, cancer, neoplasia and non-malignant hyperproliferative disorders.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: July 9, 2013
    Assignee: Novartis AG
    Inventors: Feng He, Stefan Peukert, Karen Miller-Moslin, Naeem Yusuff, Zhuoliang Chen, Bharat Lagu
  • METHODS AND COMPOSITIONS FOR TREATING LUEKEMIA
    Publication number: 20120329798
    Abstract: A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.
    Type: Application
    Filed: August 28, 2012
    Publication date: December 27, 2012
    Inventors: Mhairi Copland, Marion Dorsch, David Irvine, Paul W. Manley, Stefan Peukert
  • ORGANIC COMPOUNDS AS SMO INHIBITORS
    Publication number: 20120289507
    Abstract: The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their manufacture, where such compounds are generally pharmacologically useful as agents in therapies whose mechanism of action involve methods of inhibiting tumorigenesis, tumor growth and tumor survival using agents that inhibit the Hedgehog and Smo signaling pathway.
    Type: Application
    Filed: July 20, 2012
    Publication date: November 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Feng HE, Stefan PEUKERT, Karen MILLER-MOSLIN, Naeem YUSUFF, Zhuoliang CHEN, Bharat LAGU
  • SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP)
    Publication number: 20120202795
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Application
    Filed: April 18, 2012
    Publication date: August 9, 2012
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Philip M. WEINTRAUB, Paul R. EASTWOOD, Shujaath MEHDI, David W. STEFANY, Kwon Yon MUSICK, Neil MOORCROFT, Sungtaek LIM, John Z. JIANG, Hartmut RUTTEN, Stefan PEUKERT, Uwe SCHWAHN
  • Substituted pyridones as inhibitors of poly(ADP-ribose) polymerase (PARP)
    Patent number: 8173682
    Abstract: The present invention relates to a series of 2,3,5-substituted pyridone derivatives of formula I: wherein R, R1, R2, R3 and R4 are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are inhibitors of poly(adenosine 5?-diphosphate ribose) polymerase (PARP) and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases, including diseases associated with the central nervous system and cardiovascular disorders.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: May 8, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Philip M. Weintraub, Paul R. Eastwood, Shujaath Mehdi, David W. Stefany, Kwon Yon Musick, Neil Moorcroft, Sungtaek Lim, John Z. Jiang, Hartmut Rutten, Stefan Peukert, Uwe Schwahn
  • CYCLOHEXYLAMIN ISOQUINOLONE DERIVATIVES
    Publication number: 20110251226
    Abstract: The invention relates to 6-cyclohexylamine-substituted isoquinolone derivatives of the formula (I) or isoquinoline derivatives of the formula (I?) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 13, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • ISOQUINOLINE DERIVATIVES
    Publication number: 20110245248
    Abstract: The invention relates to 6-piperidinyl-substituted isoquinoline derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.
    Type: Application
    Filed: June 15, 2011
    Publication date: October 6, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Oliver Plettenburg, Armin Hofmeister, Dieter Kadereit, Stefan Peukert, Sven Ruf, Kurt Ritter, Matthias Loehn, Yuri Ivashchenko, Peter Monecke, Matthias Dreyer, Aimo Kannt
  • Leukemia Treatment
    Publication number: 20110039850
    Abstract: A combination of a BCR-ABL inhibitor and a hedgehog pathway inhibitor for the treatment of leukemia.
    Type: Application
    Filed: August 12, 2009
    Publication date: February 17, 2011
    Inventors: Mhairi Copland, Marion Dorsch, David Irvine, Paul W. Manley, Stefan Peukert
  • SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF
    Publication number: 20110021462
    Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.
    Type: Application
    Filed: August 4, 2010
    Publication date: January 27, 2011
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Stefan PEUKERT, Stefan GUESSREGEN, Armin HOFMEISTER, Herman SCHREUDER, Uwe SCHWAHN
  • Substituted 2-pyridone derivatives, method for their preparation and their use as medicament
    Patent number: 7863280
    Abstract: This invention relates to compounds of formula (I), wherein R1 and R3 independently represent fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; R2 represents hydrogen, fluorine, methoxy, —OCF3, C2-C3-alkenyl or C1-C4-alkyl which is optionally substituted by chlorine, methoxy or one, two or three fluorine atoms; X represents O, S, NH or N(C1-C3-alkyl); and Ar represents an unsubstituted or at least monosubstituted aryl or heteroaryl. Said compounds are inhibitors of poly(ADP-ribose) polymerase (PARP), and may be used for the treatment of a variety of disorders.
    Type: Grant
    Filed: April 11, 2007
    Date of Patent: January 4, 2011
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn
  • Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
    Patent number: 7825264
    Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: November 2, 2010
    Assignee: sanofi-aventis
    Inventors: Joachim Brendel, Heinrich Christian Englert, Stefan Peukert, Klaus Wirth, Michael Wagner, Jean-Marie Ruxer, Fabienne Pilorge
  • Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof
    Patent number: 7795278
    Abstract: This invention relates to compounds according to the general formula (I), where the definitions of the substituents R1, R2, Ar and X are as specified in the description, and to their physiologically tolerated salts, methods for the preparation of these compounds and their use as medicaments. These compounds are poly(ADP-ribose) polymerase (PARP) inhibitors.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: September 14, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Stefan Peukert, Stefan Guessregen, Armin Hofmeister, Herman Schreuder, Uwe Schwahn